Catalyst Pharmaceuticals/$CPRX
About Catalyst Pharmaceuticals
Ticker
Industry
Employees
CPRX Metrics
$2.6B
18.84
$1.18
0.75
-
Price and volume
Market cap
$2.6B
Beta
0.75
52-week high
$24.00
52-week low
$13.12
Average daily volume
1M
Financial strength
Current ratio
5.114
Quick ratio
4.75
Long term debt to equity
0.437
Total debt to equity
0.497
Management effectiveness
Return on assets (TTM)
18.35%
Return on equity (TTM)
28.29%
Valuation
Price to earnings (TTM)
18.843
Price to revenue (TTM)
5.555
Price to book
4.01
Price to tangible book (TTM)
5.35
Price to free cash flow (TTM)
13.767
Growth
Revenue change (TTM)
32.17%
Earnings per share change (TTM)
114.68%
3-year revenue growth (CAGR)
51.08%
3-year earnings per share growth (CAGR)
44.65%
What the Analysts think about CPRX
Analyst Ratings
CPRX Financial Performance
Income Statement
Q3 24
QoQ growth
$37B
-39.75%
$45B
107.52%
37.65%
6.78%
CPRX Earnings Performance
Earnings per share (EPS)
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
$3.69
$2.85
$2.45
$2.42
-
$3.55
$2.61
$2.05
$2.31
$3.94
3.94%
9.20%
19.51%
4.63%
-
CPRX News
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
FAQs
What’s the current market cap for Catalyst Pharmaceuticals stock?
What is the P/E ratio for Catalyst Pharmaceuticals stock?
Does Catalyst Pharmaceuticals stock pay dividends?
No, Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders as of January 15, 2025.
When is the next Catalyst Pharmaceuticals dividend payment date?
Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals (CPRX) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.